USPTO Patents Application 10551504

Sheet 1 of 5

Substitute Form PTO-1449 U.S. Department of Commerce
(Modified) Patent and Trademark Office

Information Disclosure Statement
^\ by Applicant

MAY 2 3 £007 r SS several sneets " necessary)
(37 CFR §1.98*%

Attorney's Docket No.

14875-153US1

Application No.

10/551,504

Applicant

Hiroyuki Tsunoda et al.

Filing Date

May 12, 2006

Group Art Unit

1644

U.S. Patent Documents

Examiner
Initial

Desig.
ID

Document
Number

Publication
Date

Patentee

Class

Subclass

Filing Date
If Appropriate

A 1

j,o / /,zyi

1)4/20/1993

Mezes et al.

A ■*>

C lOI 1 A A

o,1oj,/44

02/06/2001

uoldenberg

A 1

A3

1 1 lf\H /OA A 1

1 1/07/2001

Briggs et al.

A A
AH"

0,JHZ,ZZU

Al /OA/OAAO

Ul/2y/20U2

Adams et al.

AO

Ghetie et al.

a/;
AO

0,OoJ,l J /

Briggs et al.

A7

n7/ns/?nni

U / / KJjf Z.\J\J 1

Dllgga ci al.

A8

2002/0193571

12/19/2002

Carter et al.

A9

2003/0073161

04/17/2003

Briggs et al.

A10

2003/0148409

08/07/2003

Rossi et al.

All

2004/0091475

05/13/2004

Tsuchiya et al.

A12

2004/0242847

12/02/2004

Fukushima et al.

A13

2006/0189794

08/24/2006

Tsuchiya et al.

A14

2006/0275301

12/07/2006

Ozaki et al.

A15

2007/0003556

01/07/2007

Tsuchiya et al.

Foreign Patent Documents or Published Foreign Patent Applications

Examiner
Initial

Desig.
ID

Document
Number

Publication
Date

Country or
Patent Office

Class

Subclass

Translation

Yes

No

05/36/1908

*

"IT

05/15/204M-

JOSL

09/U/3001

13040903.

A22

WO 96/04925

02/22/1996

WIPO

A23

WO 97/31108

08/28/1997

WIPO

English
abstract

A24 WO 98/28331

ALL KbhtHLNCbS G0NSI

U

07/02/1998 WIPO

bHbD bXOtP 1 "WHERET^lD t'HROU

Gft /L.S./

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to applicant.

Substitute Disclosure Form (PTO-1449)

* denotes not considered because not in English and no
translation ,

Sheet 2 of 5

Substitute Form PTO-1449 U.S. Department of Commerce
(Modified) Patent and Trademark Office

Information Disclosure Statement
by Applicant

(Use several sheets if necessary)
(37 CFR §1 .98(b))

Attorney's Docket No.
14875-153US1

Application No.
10/551,504

Applicant

Hiroyuki Tsunoda et al.

Filing Date

May 12, 2006

Group Art Unit
1644

Foreign Patent Documents or Published Foreign Patent Applications

Examiner
Initial

Desig.
ID

Document
Number

Publication
Date

Country or
Patent Office

Class

Subclass

Translation

Yes

No

CO

A25

WO 98/41641

09/24/1998

WIPO

/L.S./

A26

WO 98/42378

10/01/1998

WIPO

/L.S./

A27

WO 99/02567

01/21/1999

WIPO

A28

WO 99/10494

03/04/1999

WIPO

A29

WO 00/67795

11/16/2000

WIPO

A30

WO 01/64713

09/07/2001

WIPO

A31

WO 01/66737

09/13/2001

WIPO

A32

WO 01/74388

10/11/2001

WIPO

All

wu ui//y4y4

WlrU

English

aDSlidCl

A34

WO 01/97858

12/27/2001

WIPO

A 1 C

A35

WO 02/0402 1

01/17/2002

WIrO

A36

WO 02/22212

03/21/2002

WIPO

A37

WO 02/33072

04/25/2002

WIPO

See A9

/L.S./

A38

WO 02/33073

04/25/2002

WIPO

See Al 1

/L.S./

A39

WO 03/033654

04/24/2003

WIPO

/L.S./

A40

WO 03/104425

12/18/2003

WIPO

/L.S./

A41

WO 2004/033499

04/22/2004

WIPO

X

/L.S./

A42

WO 2004/081048

09/23/2004

WIPO &&stra

ct or

X

/L.S./

A43

WO 2004/087763

10/14/2004

.est or

ly

X

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner
Initial

Desig.
ID

Document

/L.S./

A44

Ballmaier et al., "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia,"
Blood, 97:139-146 (2001)

/L.S./

A45

Brinkmann et al., "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in
transplantation and autoimmunity," Curr. Opin, Immunol, 14:569-575 (2002)

/L.S./

A46

Bruenke et al., "A recombinant bispecific single-chain Fv antibody against HLA class II and FcyRIII
(CD16) triggers effective lysis of lymphoma cells," Br. J. Haematol, 125:167-179 (2004)

/L.S./

A47

Clark, "CD22, a B Cell-Specific Receptor, Mediates Adhesion and Signal Transduction,"
J. Immunol, 150:4715-4718 (1993)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Sheet 3 of 5

Substitute Form PTO-1449 U.S. Department of Commerce
(Modified) Patent and Trademark Office

Information Disclosure Statement
by Applicant

(Use several sheets if necessary)
(37 CFR §1 .98(b))

Attorney's Docket No.
14875-153US1

Application No.
10/551,504

Applicant

Hiroyuki Tsunoda et al.

Filing Date

May 12, 2006

Group Art Unit

1644

<

Dther Documents (include Author, Title, Date, and Place of Publication)

Examiner
Initial

Desig.
ID

Document

/L.S./

A48

Co et al., A Humanized Antibody Specific tor the Platelet Integnn gpllb/Illa, J. Immunol.,
152:2968-2976(1994)

/L.S./

A49

Daniel et al., "Induction of Apoptosis in Human Lymphocytes by Human Anti-HLA Class I
Antibodies," Transplantation, 75:1380-1386 (2003)

/I Q /
IL.O.I

A50

T"\ 1"* 1 * a 1 6 CT\ * £C , ■ 1 1, If" 1" J1 \ ' A a. a. C

De Felice et al., Differential regulatory role of monomorphic and polymorphic determinants or
histocompatibility leukocyte antigen class I antigens in monoclonal antibody OKT3-induced T cell
proliferation, J. Immunol., 139:2683-2689 (1987)

/L.S./

A C 1

A51

DeNardo et al., "Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design
Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy, Cancer Biother.
Radiopharm., 16:525-535 (2001)

/L.S./

A52

Deng et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates
Megakaryocytopoiesis," Blood, 92:1981-1988 (1998)

/L.S./

A53

Ebert et al., "Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric
Cancer," Cancer Res., 60:1995-2001 (2000)

/L.S./

A54

tiiiott et at., Activation ot tne Erythropoietin (fcrU) Keceptor by Bivalent Anti-c.rU Keceptor
Antibodies," J. Biol. Chem., 271:24691-24697 (1996)

/L.S./

A55

Fayen et al., "Negative signaling by anti-HLA class I antibodies is dependent upon two triggering
events, Int. Immunol., 10:1347-1358 (1998)

/L.S./

A56

Funaro et al., "Monoclonal antibodies and therapy of human cancers," Biotechnol. Adv., 18:385-401
(2000)

/L.S./

A57

Genestier et al., Antibodies to HLA Class 1 al Domain Trigger Apoptosis of CD40-Activated
Human B Lymphocytes," Blood, 90:726-735 (1997)

/L.S./

A58

Genestier et al., "Caspase-dependent Ceramide Production in Fas- and HLA Class I-mediated
Peripheral T Cell Apoptosis," J. Biol. Chem., 273:5060-5066 (1998)

/L.S./

A59

Genestier et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the
HLA Class I al Domain, Blood, 90:3629-3639 (1997)

/L.S./

A60

Genestier et al., "T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2
and mterleukin-4, Eur. J. Immunol., 27:495-499 (1997)

/L.S./

A61

Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases then-
ability to induce growth arrest or apoptosis of tumor cells," Proc. Natl. Acad. Sci. USA,
94:7509-7514(1997)

/L.S./

A62

Goel et al., " Wm Tc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging
Agents for Rapid In Vivo Localization of Human Colon Carcinoma," J. Nucl. Med., 42:1519-1527
(2001)

/L.S./

A63

Goel et al., "Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal
Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application," Cancer Res.,
60:6964-6971 (2000)

CO

j

A64

Goto et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated
Human B Cells," Blood, 84:1922-1930 (1994)

/L.S./

A65

Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," Proc. Natl. Acad.
Sci. USA, 90:6444-6448 (1993)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Sheet 4 of 5

Substitute Form PTO-1449 U.S. Department of Commerce
(Modified) Patent and Trademark Office

Information Disclosure Statement
by Applicant

(Use several sheets if necessary)

(37 CFR§1 .98(b))

Attorney's Docket No.
14875-153US1

Application No.

10/551,504

Applicant

Hiroyuki Tsunoda et al.

Filing Date

May 12, 2006

Group Art Unit
1644

Other Documents (include Author, Title, Date, and Place of Publication)

examiner
Initial

Desig.
ID

Document

/L.S./

A66

Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment
(Single-Chain Fv-C H 3) Which Exhibits Rapid, High-Level Targeting of Xenografts," Cancer Res.,
56:3055-3061 (1996)

/L.S./

A67

Hudson et al., "High avidity scFv multimers; diabodies and triabodies," J. Immunol. Methods,
231:177-189(1999)

/L.S./

A68

Kikuchi et al., "A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic
cells, mocnem. tsiopnys. Kes. Commun., Jl3:y lz-y is (ZUU4)

/I Q /

IL.O.I

Kimura et al., "2D7 diabody bound to the cd domain of HLA class I efficiently induces caspase-
independent cell death against malignant and activated lymphoid cells," Biochem. Biophys. Res.
Commun., 325:1201-1209 (2004)

IS/

A70

Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific
single-chain rv Antibodies, J. Mol. awl., 330:99-1 1 1 (2003)

/L.S./

A71

Kortt et al., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting," Biomol.
hng., 18:95-108 (2001)

/L.S./

A72

Kreitman et al., "Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin
RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias,"

/~t ?•„ /t n /.i ^n/ i ,101 f\f\e\\

Clin. Cancer Res., 6:1476-1487 (2000)

/L.S./

A73

Kulkarni et al., "Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal
Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility
Complex," Transplant. Proc, 30:1081 (1998)

/L.S,/

A74

Kulkarni et al., "Programmed Cell Death Signaling Via Cell-Surface Expression of a Single-Chain
Antibody Transgene," Transplantation, 69:1209-1217 (2000)

/L.S./

A75

Lebrun et al., "Antibodies to the Extracellular Receptor Domain Restore the Hormone-insensitive
Kinase and Conformation of the Mutant Insulin Receptor Valine 382," J. Biol. Chem.,
268:11272-11277(1993)

/L.S./

A76

Li et al., "The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22
Antibodies," Cell. Immunol, 1 18:85-99 (1989)

CO

A77

Matsuoka et al., "A Monoclonal Antibody to the oil Domain of Murine Major Histocompatibility
Complex Class I that Specifically Kills Activated Lymphocytes and Blocks Liver Damage in the
Concanavalin A Hepatitis Model,"/. Exp. Med., 198:497-503 (2003)

/L.S./

A78

Matsuoka et al., "A Novel Type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody
without Participation of Complement,"/. Exp. Med., 181:2007-2015 (1995)

/L.S./

A79

Nishii, "CD22 antibody therapy," Current Therapy, 20:47-50 (2001) (English translation included)

/L.S./

A80

Ohtomo et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially
Overexpressed on Multiple Myeloma Cells," Biochem. Biophys. Res. Commun., 258:583-591 (1999)

/L.S./

A81

Oka, "Development of Novel Immunotoxin Using Recombinant Alpha-Sarcin and Its Application
Treatment of Hematopoietic Tumor," Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu
Hokokushu, 12:46-56 (1998) (concise English explanation included)

/L.S./

A82

Ono et al., "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by
human effector cell-mediated cyto-toxicity," Mol. Immunol, 36:387-395 (1999)

/L.S./

A83

Orita et al., "A novel therapeutic approach for thrombocytopenia by minibody agonist of the
thrombopoietin receptor," Blood, 105:562-566 (2005)

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Substitute Disclosure Form (PTO-1449)

Sheet 5 of 5

Substitute Form PTO-1449 U.S. Department of Commerce
(Modified) Patent and Trademark Office

Information Disclosure Statement
by Applicant

(Use several sheets if necessary)
(37 CFR §1 .98(b))

Attorney's Docket No.

14875-153US1

Application No.

10/551,504

Applicant

Hiroyuki Tsunoda et al.

Filing Date

May 12, 2006

Group Art Unit

1644

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner
Initial

Desig.

ID

Document

/L.S./

A84

Ozaki et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in
Human Lymphoid Malignancies, Blood, 102:933a, Abstract No. 3474 (2003)

/L.S./

A85

Ozaki et al., "Humanized Anti-HM 1 .24 Antibody Mediates Myeloma Cell Cytotoxicity That Is
fcnnanced oy cytokine Mimulation 01 biiector Cells, Blood, 93.3y22-3y5\J (lyy9)

/L.S./

A86

Ozaki et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against
a riasma ceii-apecinc Antigen, HMl.z4, Blood, yo:3179-iloo (19y7)

/L.S./

Ao /

Pettersen et al., "The TCR-Binding Region of the HLA Class I 04 Domain Signals Rapid Fas-
independent Cell Death: A Direct Pathway lor 1 Cell-Mediated Killing ot Target Cells " J.
Immunol., 160:4343-4352 (1998)

/L.S./

A88

Pi6tri-Rouxel et al., "The biochemical effect of the naturally occurring Trp64-» Arg mutation on
human pi -adrenoceptor activity, Eur. J. Bwchem. , 247: 1 1 74- 1 1 79 (1 997)

/L.S./

A89

Pliickthun et al., "New protein engineering approaches to multivalent and bispecific antibody
fragments, Immunotechnology, 3:83-105 (1997)

/L.S./

A90

Rossi et al., "Development of New Multivalent-bispecific Agents for Pretargeting Tumor
Localization and Therapy, Clin. Cancer Res., 9:3886s-3896s (2003)

i L.O./

A91

Sato et al., "CD22 Is Both a Positive and Negative Regulator of B Lymphocyte Antigen Receptor
Signal Transduction: Altered Signaling in CD22-Deficient Mice," Immunity, 5:551-562 (1996)

/L.S./

A92

Scheurle et al., Cancer Gene Discovery Using Digital Differential Display, Cancer Res.,
60:4037-4043 (2000)

/L.S./

A93

Smith et al., Inhibition of T Cell Activation by a Monoclonal Antibody Reactive Against the cQ
Domain of Human MHC Class I Molecules," J. Immunol., 153:1054-1067 (1994)

/L.S./

A94

Tahtis et al., Biodistnbution Properties of Indium-labeled C-Functionahzed /ra/w-Cyclohexyl
Diethylenetriaminepentaacetic Acid Humanized 3S193 Diabody and F(ab')2 Constructs in a Breast
Carcinoma Xenograft Model, Clin. Cancer Res., 7:1061-1072 (2001)

/L.S./

A95

Tedder et al., "CD22, a B Lymphocyte-Specific Adhesion Molecule That Regulates Antigen
Receptor Signaling," Annu. Rev. Immunol., 15:481-504 (1997)

/L.S./

A96

Thilenius et al., "Agonist antibody and Fas ligand mediate different sensitivity to death in the
signaling pathways of Fas and cytoplasmic mutants," Eur. J. Immunol., 27:1108-1114 (1997)

■ 11 S /'

A97

Woodle et al., Anti-Human Class I o3 Domain-Specific Monoclonal Antibody Induces
Programmed Cell Death in Murine Cells Expressing Human Class I MHC Transgenes," Transplant.
Proc, 30:1059-1060 (1998)

/L.S./

A98

Woodle et al, "Anti-Human Class I MHC Antibodies Induce Apoptosis by a Pathway That Is
Distinct from the Fas Antigen-Mediated Pathway," J. Immunol, 158:2156-2164 (1997)

/L.S./

A99

Woodle et al., "Class I MHC Mediates Programmed Cell Death in Human Lymphoid Cells,"
Transplantation, 64:140-146 (1997)

/L.S./

A100

Wu et al., "Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent
dimers," Immunotechnology, 2:21-36 (1996)

/L.S./

A101

Xiong et al., "Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-
CD3 bispecific diabody," Cancer Lett., 177:29-39 (2002)

/L.S./

A102

Xu et al., "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene
expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver,"
Proc. Natl. Acad. Sci. USA, 98: 15089-15094 (2001)

Examiner Signature

/Lorraine Specter/

Date Considered

03/23/2009

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
next communication to applicant.

Substitute Disclosure Form (PTO-1449)